Valuation : Tonix Pharmaceuticals

Market Cap 226M 194M 183M 167M 312M 21.48B 313M 2.17B 838M 10.94B 848M 829M 34.66B P/E 2026 *
-1.34x
P/E 2027 * -1.99x
Enterprise Value 226M 194M 183M 167M 312M 21.48B 313M 2.17B 838M 10.94B 848M 829M 34.66B EV / Sales 2026 *
4.1x
EV / Sales 2027 * 2.04x
Free-Float
99.84%
Yield 2026 *
-
Yield 2027 * -
09-08 Tonix Pharmaceuticals Holding Corp. Announces Appointment of Thomas Englese to Chief Commercial Officer, Effective September 8, 2026 CI
08-19 Tonix Pharmaceuticals Holding Corp. Announces Appointment of Seth Lederman as Interim Chief Medical Officer CI
08-10 Tonix Pharmaceuticals Holding Corp., Q2 2026 Earnings Call, Aug 10, 2026
08-10 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-04 Tonix Pharmaceuticals Announces Positive Minutes From Type C FDA Meeting To Discuss Adaptive Phase 2 Field Study Of TNX-4800, A Human, Anti-OspA Monoclonal Antibody, To Prevent Lyme Disease In The US CI
07-22 Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026 CI
07-15 Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease CI
07-13 Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage CI
07-13 Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment MT
06-29 Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study MT
06-29 Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder CI
06-25 Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT MT
06-08 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
Manager TitleAgeSince
Chief Executive Officer 68 16/11/2007
Director of Finance/CFO 52 01/02/2016
Chief Tech/Sci/R&D Officer 57 04/02/2025
Director TitleAgeSince
Chairman 68 01/10/2011
Director/Board Member 66 12/09/2017
Director/Board Member 81 05/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
-2.36%+2.32% - - 226M
+0.07%-3.02%+49.89%+88.91% 1,002B
-0.56%-2.93%+50.97%+64.24% 649B
-0.06%-4.86%+18.33%+67.06% 440B
-0.80%-0.43%+28.92%+36.94% 346B
-0.13%-14.97%+9.41%+26.44% 263B
-1.90%-2.72%-2.72%+10.93% 250B
-0.62%-11.64%+39.76%+49.50% 213B
-1.06%-4.23%-14.70%-57.76% 201B
-0.52%-2.45%+26.08%+89.44% 182B
Average -0.78%-2.06%+22.88%+41.75% 393.74B
Weighted average by Cap. -0.42%-2.39%+31.92%+55.83%

Financials

2026 *2027 *
Net sales 55M 47.33M 44.57M 40.61M 75.98M 5.23B 76.28M 528M 204M 2.67B 207M 202M 8.45B 111M 95.42M 89.85M 81.86M 153M 10.55B 154M 1.06B 412M 5.38B 416M 407M 17.03B
Net income -169M -145M -137M -125M -233M -16.06B -234M -1.62B -626M -8.18B -634M -620M -25.91B -164M -141M -133M -121M -227M -15.63B -228M -1.58B -610M -7.96B -617M -604M -25.23B
Net Debt - -
Logo Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.16USD
Average target price
42.40USD
Spread / Average Target
+222.19%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!